

CITATION REPORT

List of articles citing

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

DOI: 10.1177/1758834014544121

Therapeutic Advances in Medical Oncology, 2014, 6, 229-39.

Source: <https://exaly.com/paper-pdf/57666407/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|-------|-----------|
| 174 | Advantages of the avian model for human ovarian cancer. <i>Molecular and Clinical Oncology</i> , 2015 , 3, 1191-1198 | 1.698 | 4 |
| 173 | Pharmacodynamic study of I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer. 2015 , 10, 572-578 | | 2 |
| 172 | Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy. 2015 , 15, 784 | | 10 |
| 171 | Olaparib in the management of ovarian cancer. 2015 , 8, 127-35 | | 27 |
| 170 | Albumin-bound paclitaxel in solid tumors: clinical development and future directions. 2015 , 9, 3767-77 | | 132 |
| 169 | The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer. 2015 , 36, 4939-48 | | 38 |
| 168 | Folate receptor: a potential target in ovarian cancer. 2015 , 26, 1-12 | | 6 |
| 167 | HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 1608-15 | 3.5 | 7 |
| 166 | Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. 2015 , 12, 580-91 | | 63 |
| 165 | Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays. <i>Gynecologic Oncology</i> , 2015 , 138, 181-9 | 4.9 | 85 |
| 164 | Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. 2015 , 11, 1653-67 | | 9 |
| 163 | Conditioned media from human ovarian cancer endothelial progenitor cells induces ovarian cancer cell migration by activating epithelial-to-mesenchymal transition. 2015 , 22, 518-23 | | 6 |
| 162 | Immunotherapy for ovarian cancer: what are the targets of the future?. 2015 , 11, 1293-6 | | 11 |
| 161 | Genomics-Guided Immunotherapy of Human Epithelial Ovarian Cancer. 2016 , 237-250 | | 1 |
| 160 | Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids. <i>Oncotarget</i> , 2016 , 7, 86374-86387 | 3.3 | 22 |
| 159 | Metronomic Chemotherapy: Seems Prowess to Battle against Cancer in Current Scenario. 2016 , 10, FC09-FC13 | | 4 |
| 158 | In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. <i>Frontiers in Oncology</i> , 2016 , 6, 164 | 5.3 | 7 |

| | | | |
|-----|--|------|----|
| 157 | High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 640-7 | 3.5 | 2 |
| 156 | Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. 2016 , 18, 775-784 | | 41 |
| 155 | Minireview: Regulatory T Cells and Ovarian Cancer. 2016 , 45, 712-720 | | 13 |
| 154 | Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis. <i>Supportive Care in Cancer</i> , 2016 , 24, 2635-42 | 3.9 | 10 |
| 153 | A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity. 2016 , 15, 280-90 | | 17 |
| 152 | Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2017 , 144, 480-485 | 4.9 | 10 |
| 151 | Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells. 2017 , 136, 40-50 | | 11 |
| 150 | Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells. 2017 , 90, 854-866 | | 5 |
| 149 | Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. <i>Annals of Oncology</i> , 2017 , 28, 1842-1848 | 10.3 | 23 |
| 148 | Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: Preliminary results. 2017 , 47, 244-250 | | 18 |
| 147 | Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells. 2017 , 6, 856-865 | | 10 |
| 146 | A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2017 , 147, 276-282 | 4.9 | 7 |
| 145 | A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. <i>Gynecologic Oncology</i> , 2017 , 146, 484-490 | 4.9 | 57 |
| 144 | Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids. <i>Clinical Cancer Research</i> , 2017 , 23, 6934-6945 | 12.9 | 56 |
| 143 | Detection and Characterization by Immunohistochemistry of the NGcGM3 Ganglioside in the Chicken Animal Model of Ovarian Cancer. 2017 , 03, | | |
| 142 | HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity Studies. 2017 , 8, 498 | | 12 |
| 141 | The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2017 , 18, | 6.3 | 16 |
| 140 | Clinical significance and biological role of Wnt10a in ovarian cancer. <i>Oncology Letters</i> , 2017 , 14, 6611-6617 | 7 | 7 |

| | | | |
|-----|---|------|----|
| 139 | Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis. 2017 , 10, 973-984 | | 11 |
| 138 | Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018 , 14, 1395-1405 | 6 | 16 |
| 137 | The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. 2018 , 102, 1127-1144 | | 27 |
| 136 | FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. 2018 , 14, 1669-1678 | | 43 |
| 135 | Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. <i>International Journal of Biochemistry and Cell Biology</i> , 2018 , 95, 9-16 | 5.6 | 67 |
| 134 | Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models. 2018 , 169, 1-10 | | 47 |
| 133 | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. 2018 , 14, 123-136 | | 37 |
| 132 | Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival. <i>Oncotarget</i> , 2018 , 9, 35162-35180 | 3.3 | 5 |
| 131 | ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2. 2018 , 63, 262-271 | | 24 |
| 130 | Clinical Utility of Poly (ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer. 2018 , 10, | | |
| 129 | Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. <i>Cancers</i> , 2018 , 10, | 6.6 | 82 |
| 128 | Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta. <i>Cancer Science</i> , 2018 , 109, 3403-3410 | 6.9 | 9 |
| 127 | Genomic Copy Number Alterations in Serous Ovarian Cancer. 2018 , | | |
| 126 | Safety and dose modification for patients receiving niraparib. <i>Annals of Oncology</i> , 2018 , 29, 1784-1792 | 10.3 | 78 |
| 125 | Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine. 2018 , 44, 1330-1334 | | 7 |
| 124 | Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. 2018 , 128, 30-42 | | 9 |
| 123 | Forkhead-box R2 promotes metastasis and growth by stimulating angiogenesis and activating hedgehog signaling pathway in ovarian cancer. 2018 , 119, 7780-7789 | | 7 |
| 122 | p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLI pathways. 2018 , 7, | | 47 |

| | | | |
|-----|--|-----|----|
| 121 | Zeylenone inhibits proliferation and promotes apoptosis in ovarian carcinoma cells via Janus kinase 2 / signal transducers and activators of transcription 3 pathways. 2018 , 44, 1451-1457 | | 4 |
| 120 | Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas. <i>Gynecologic Oncology</i> , 2018 , 150, 534-544 | 4.9 | 20 |
| 119 | Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells. 2018 , 78, 3560-3573 | | 35 |
| 118 | Chrysophanol induces cell death and inhibits invasiveness via mitochondrial calcium overload in ovarian cancer cells. 2018 , 119, 10216-10227 | | 17 |
| 117 | Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2018 , 151, 46-52 | 4.9 | 29 |
| 116 | Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. <i>Journal of Ovarian Research</i> , 2018 , 11, 43 | 5.5 | 39 |
| 115 | Niraparib for the treatment of ovarian cancer. 2018 , 18, 727-733 | | 10 |
| 114 | Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity. 2019 , 11, 7111-7122 | | 8 |
| 113 | Metastasis of ovarian cancer to the bile duct: a case report. 2019 , 5, 100 | | 4 |
| 112 | Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases. 2019 , 120, 794-802 | | 14 |
| 111 | LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145. 2019 , 58, 2286-2296 | | 50 |
| 110 | Olaparib Quantification in Human Plasma for Clinical Purposes using High-Performance Liquid Chromatography with UV detector. 2019 , 9, 526-534 | | 0 |
| 109 | ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer. <i>Cancers</i> , 2019 , 11, | 6.6 | 8 |
| 108 | A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy. 2019 , 27, 1203-1209 | | 1 |
| 107 | [MSI Metastatic solid tumors treatment and immunotherapies]. 2019 , 106, 143-150 | | 2 |
| 106 | p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy. 2019 , 16, 3386-3398 | | 9 |
| 105 | Ovarian cancer relapse: From the latest scientific evidence to the best practice. 2019 , 140, 28-38 | | 18 |
| 104 | Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53. <i>Journal of Ovarian Research</i> , 2019 , 12, 45 | 5.5 | 4 |

| | | | |
|-----|--|-----|----|
| 103 | Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer. <i>Journal of Ovarian Research</i> , 2019 , 12, 38 | 5.5 | 4 |
| 102 | A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study. <i>Frontiers in Oncology</i> , 2019 , 9, 255 | 5.3 | 25 |
| 101 | DBC1 Regulates p53 Stability via Inhibition of CBP-Dependent p53 Polyubiquitination. 2019 , 26, 3323-3335.e4 | 7 | |
| 100 | Tailoring Ovarian Cancer Treatment: Implications of Mutations. <i>Cancers</i> , 2019 , 11, | 6.6 | 34 |
| 99 | Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. <i>European Journal of Medicinal Chemistry</i> , 2019 , 170, 16-27 | 6.8 | 4 |
| 98 | Expression of integrin $\beta 6$ is associated with multi drug resistance and prognosis in ovarian cancer. <i>Oncology Letters</i> , 2019 , 17, 3974-3980 | 2.6 | 8 |
| 97 | Intraperitoneal Chemotherapy: The Lived Experiences of Taiwanese Patients With Ovarian Cancer. 2019 , 23, E100-E106 | | 4 |
| 96 | Integrated Chinese Herbal Medicine Therapy Improves the Survival of Patients With Ovarian Cancer. 2019 , 18, 153473541988149 | | 2 |
| 95 | Wnt/ β catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis. <i>Journal of Ovarian Research</i> , 2019 , 12, 122 | 5.5 | 80 |
| 94 | An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinum-resistant epithelial ovarian cancer. 2019 , | | 1 |
| 93 | Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2019 , 152, 416-425 | 4.9 | 24 |
| 92 | Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. 2019 , 1863, 371-378 | | 27 |
| 91 | Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach. 2019 , 25, 1417-1430 | | 1 |
| 90 | Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer. 2019 , 132, 171-177 | | 56 |
| 89 | Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model. 2019 , 32, e4016 | | 4 |
| 88 | Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. 2019 , 76, 681-697 | | 58 |
| 87 | Ovarian cancer stem cells and their role in drug resistance. <i>International Journal of Biochemistry and Cell Biology</i> , 2019 , 106, 117-126 | 5.6 | 32 |
| 86 | Chitosan is a potential inhibitor of ovarian cancer: Molecular aspects. 2020 , 72, 687-697 | | |

| | | | |
|----|--|------|----|
| 85 | Theranostic Layer-by-Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing. 2020 , 132, 2798-2805 | | 3 |
| 84 | Theranostic Layer-by-Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing. 2020 , 59, 2776-2783 | | 31 |
| 83 | Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers. <i>Gynecologic Oncology</i> , 2020 , 159, 611-617 | 4.9 | 3 |
| 82 | Treatment of epithelial ovarian cancer. 2020 , 371, m3773 | | 88 |
| 81 | Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. <i>Cancers</i> , 2020 , 12, | 6.6 | 5 |
| 80 | In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses. 2020 , 14, 2436-2454 | | 3 |
| 79 | Surgery chemotherapy for ovarian cancer recurrence: what is the best treatment option. 2020 , 9, 1112-1117 | | 5 |
| 78 | Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. 2020 , 40, 5255-5261 | | 2 |
| 77 | Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. 2020 , 18, 236 | | 11 |
| 76 | Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1026-1033 | 3.5 | 2 |
| 75 | Stereotactic body radiation therapy in the treatment of ovarian cancer. 2020 , 15, 108 | | 6 |
| 74 | Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 779-792 | 5.9 | 3 |
| 73 | Epidemiology and Genetic Susceptibility of Breast and Ovarian Cancer in Sardinian Population. 2020 , | | |
| 72 | Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. <i>Drug Discovery Today</i> , 2020 , 25, 1232-1238 | 8.8 | 9 |
| 71 | Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 15 |
| 70 | Antibody-drug conjugates for the treatment of ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 875-887 | 5.4 | 3 |
| 69 | Nanoparticle delivery systems to combat drug resistance in ovarian cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021 , 31, 102309 | 6 | 10 |
| 68 | LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. <i>Seminars in Cancer Biology</i> , 2021 , 73, 134-157 | 12.7 | 5 |

| | | | |
|----|---|------|----|
| 67 | The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 285-311 | 2.5 | 2 |
| 66 | Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2021 , 14, 12 | 5.5 | 2 |
| 65 | KAT6A, a novel regulator of Eatenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1. <i>Theranostics</i> , 2021 , 11, 6278-6292 | 12.1 | 4 |
| 64 | Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a. <i>Human Cell</i> , 2021 , 34, 579-587 | 4.5 | 4 |
| 63 | Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant Liposomes. <i>Pharmaceutics</i> , 2021 , 13, | 6.4 | 1 |
| 62 | Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 116 | 12.8 | 4 |
| 61 | Tamoxifen and aromatase inhibitors for relapse of tubo-ovarian high-grade serous cancer. <i>The Cochrane Library</i> , | 5.2 | 78 |
| 60 | Analysis of the association between KIN17 expression and the clinical features/prognosis of epithelial ovarian cancer, and the effects of KIN17 in SKOV3 cells. <i>Oncology Letters</i> , 2021 , 21, 475 | 2.6 | 3 |
| 59 | Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021 , 13, | 6.6 | 4 |
| 58 | Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021 , 125, 265-276 | 8.7 | 1 |
| 57 | ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity. <i>Cancer Medicine</i> , 2021 , 10, 3373-3387 | 4.8 | 1 |
| 56 | Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18, | 4.6 | 0 |
| 55 | A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). <i>International Journal of Oncology</i> , 2021 , 59, | 4.4 | 10 |
| 54 | Association of patient-reported outcomes and ovarian cancer recurrence. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1248-1259 | 3.5 | 1 |
| 53 | The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. <i>Cancers</i> , 2021 , 13, | 6.6 | 1 |
| 52 | Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1542-1549 | 6.1 | 2 |
| 51 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. <i>Annals of Oncology</i> , 2021 , 32, 757-765 | 10.3 | 17 |
| 50 | NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 652325 | 5.7 | 1 |

| | | | |
|----|---|------|----|
| 49 | Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. <i>Oncogenesis</i> , 2021 , 10, 48 | 6.6 | 2 |
| 48 | Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. <i>Seminars in Cancer Biology</i> , 2021 , 77, 144-166 | 12.7 | 7 |
| 47 | Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 0 |
| 46 | Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. <i>Seminars in Cancer Biology</i> , 2021 , 77, 99-109 | 12.7 | 5 |
| 45 | Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). <i>Journal of Clinical Oncology</i> , 2021 , 39, 3671-3681 | 2.2 | 15 |
| 44 | RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3145-57 | 15.9 | 54 |
| 43 | Methyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death: Potential use as adjunctive to chemotherapy. <i>PLoS ONE</i> , 2017 , 12, e0182789 | 3.7 | 4 |
| 42 | Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 69779-69796 | 3.3 | 18 |
| 41 | Studies of lncRNAs in DNA double strand break repair: what is new?. <i>Oncotarget</i> , 2017 , 8, 102690-102704. | 3.3 | 6 |
| 40 | Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 51-55 | 1.6 | 1 |
| 39 | The promise and challenge of ovarian cancer models. <i>Translational Cancer Research</i> , 2015 , 4, 14-28 | 0.3 | 27 |
| 38 | PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021 , 13, | 6.6 | 1 |
| 37 | Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2021 , | 12.9 | 1 |
| 36 | A case report of long term bevacizumab treatment in multiresistant ovarian cancer. <i>International Journal of Cancer Therapy and Oncology</i> , 2016 , 4, 4214 | | |
| 35 | p53 suppresses mutagenic RAD52 and POLI pathways by orchestrating DNA replication restart homeostasis. | | 0 |
| 34 | Health care priority and rare malignant diseases: Orphan therapy in brca 1/2 mutated ovarian cancer -experience from Montenegro. <i>Medicinski Casopis</i> , 2019 , 53, 64-69 | 0.1 | |
| 33 | Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence.. 2019 , 2, 1127-1135 | | 0 |
| 32 | Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023. <i>Cancer Science</i> , 2021 , | 6.9 | 4 |

| | | | |
|----|---|-----|----|
| 31 | Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound. <i>Gynecologic Oncology</i> , 2021 , | 4.9 | 1 |
| 30 | Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. 2020 , 8, | | 2 |
| 29 | A CT-based radiomics nomogram for predicting early recurrence in patients with high-grade serous ovarian cancer. <i>European Journal of Radiology</i> , 2021 , 145, 110018 | 4.7 | 2 |
| 28 | Approaches to identifying synthetic lethal interactions in cancer. <i>Yale Journal of Biology and Medicine</i> , 2015 , 88, 145-55 | 2.4 | 28 |
| 27 | Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. <i>European Journal of Medicinal Chemistry</i> , 2021 , 228, 113978 | 6.8 | 0 |
| 26 | High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 761960 | 5.3 | 1 |
| 25 | Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET.. <i>Oncogene</i> , 2022 , | 9.2 | 2 |
| 24 | Multi-Omics Analysis of the Therapeutic Value of MAL2 Based on Data Mining in Human Cancers.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 736649 | 5.7 | 0 |
| 23 | Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements.. <i>Cells</i> , 2022 , 11, | 7.9 | 4 |
| 22 | Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer.. <i>Cells</i> , 2022 , 11, | 7.9 | 1 |
| 21 | CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives.. <i>International Journal of Molecular Sciences</i> , 2022 , 23, | 6.3 | 1 |
| 20 | ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.. <i>Cell Death and Disease</i> , 2022 , 13, 239 | 9.8 | 1 |
| 19 | Wnt Antagonist as therapeutic targets in Ovarian Cancer.. <i>International Journal of Biochemistry and Cell Biology</i> , 2022 , 106191 | 5.6 | 2 |
| 18 | Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature.. <i>Supportive Care in Cancer</i> , 2022 , 1 | 3.9 | 0 |
| 17 | Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines. <i>Cancers</i> , 2022 , 14, 2362 | 6.6 | 1 |
| 16 | Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting. <i>Medicina (Lithuania)</i> , 2022 , 58, 649 | 3.1 | |
| 15 | Comprehensive Network Analysis of Dysregulated Genes Revealed MNX1-AS1/ hsa-miR-4697-3p/ HOXB13 Axis in OC Chemotherapy Response. <i>Cancer Science</i> , | 6.9 | 0 |
| 14 | The effect of calycosin-7-O-β-D-glucoside and its synergistic augmentation of cisplatin-induced apoptosis in SK-OV-3 cells. <i>Current Pharmaceutical Design</i> , 2022 , 28, | 3.3 | 0 |

| | | |
|----|---|---|
| 13 | Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer. | |
| 12 | Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy. 13, | 1 |
| 11 | Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report. 2022, | 0 |
| 10 | Anti-tumor Treatment Targeting NaPi2b in Ovarian Cancer. 2022, 102489 | 0 |
| 9 | A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. 13, | 0 |
| 8 | Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer. | 0 |
| 7 | The Development of a Three-Dimensional Platform for Patient-Derived Ovarian Cancer Tissue Models: A Systematic Literature Review. 2022, 14, 5628 | 1 |
| 6 | The role of miRNAs in Ovarian Cancer Pathogenesis and Therapeutic Resistance - A Focus on Signaling Pathways Interplay. 2022, 154222 | 0 |
| 5 | Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study. 2023, 169, 118-124 | 0 |
| 4 | Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis. 2023, 13, 1040 | 0 |
| 3 | Systemic Treatment Sequencing and Prediction of First-line Therapy Outcomes in Recurrent or Metastatic Head and Neck Cancer. 2023, 199-215 | 0 |
| 2 | Small-scale variants and large deletions in BRCA1/2 genes in Slovak high-grade serous ovarian cancer. 2023, 154475 | 0 |
| 1 | UBP43 promotes epithelial ovarian carcinogenesis via activation of β -catenin signaling pathway. | 0 |